We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

15 hedge funds and large institutions have $131K invested in InVivo Therapeutics Holdings Corp in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

6% more capital invested

Capital invested by funds: $124K → $131K (+$7.3K)

25% less funds holding

Funds holding: 20 → 15 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
15
Holders Change
-5
Holders Change %
-25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$7.94K
2
TRCT
Tower Research Capital (TRC)
New York
+$7.13K
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$93
4
Wells Fargo
Wells Fargo
California
+$11

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$14K
2
TSS
Two Sigma Securities
New York
-$13.6K
3
UBS Group
UBS Group
Switzerland
-$4.75K
4
Morgan Stanley
Morgan Stanley
New York
-$1.52K
5
National Bank of Canada
National Bank of Canada
Quebec, Canada
-$21
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$46.9K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$35.4K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$23K +$7.94K +6,241 +57%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$15.2K – – –
TRCT
5
Tower Research Capital (TRC)
New York
$9.98K +$7.13K +5,607 +314%
Morgan Stanley
6
Morgan Stanley
New York
$364 -$1.52K -1,199 -82%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$99 +$93 +73 New
Wells Fargo
8
Wells Fargo
California
$30 +$11 +9 +69%
TWC
9
TD Waterhouse Canada
Ontario, Canada
$11 – – –
Osaic Holdings
10
Osaic Holdings
Arizona
$8 – – –
CTA
11
Colonial Trust Advisors
South Carolina
$3 – – –
AF
12
Allworth Financial
California
$2 – – –
UBS Group
13
UBS Group
Switzerland
$1 -$4.75K -3,739 -100%
SWM
14
Sugarloaf Wealth Management
Georgia
$1 – – –
WP
15
WealthPLAN Partners
Nebraska
$1 – – –
Millennium Management
16
Millennium Management
New York
– -$14K -13,280 Closed
TSS
17
Two Sigma Securities
New York
– -$13.6K -12,870 Closed
National Bank of Canada
18
National Bank of Canada
Quebec, Canada
– -$21 -20 Closed
FFA
19
Farther Finance Advisors
California
– -$2 -2 Closed
MIA
20
Milestone Investment Advisors
Wisconsin
– -$2 -1 Closed

NVIV Hedge Fund Activity: Q2 2023 in Review

15 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q2 2023, worth a combined $131K — up 5.9% from $124K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of NVIV and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $7.94K. The largest seller was Millennium Management, exiting entirely with an estimated $14K sold.

  • 15 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q2 2023, down from 20 in Q1 2023.
  • Funds reported $131K of InVivo Therapeutics Holdings Corp stock for Q2 2023, up 5.9% quarter-over-quarter.
  • 1 fund opened new InVivo Therapeutics Holdings Corp positions in Q2 2023 and 6 closed out, a net change of -5 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q2 2023 was Renaissance Technologies, an estimated $7.94K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q2 2023 was Millennium Management, an estimated $14K sold.

Based on aggregated 13F filings for Q2 2023.